GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010948 | Liver | HCC | negative regulation of cell cycle process | 152/7958 | 294/18723 | 8.50e-04 | 5.08e-03 | 152 |
GO:004593111 | Liver | HCC | positive regulation of mitotic cell cycle | 69/7958 | 121/18723 | 8.79e-04 | 5.20e-03 | 69 |
GO:1901991 | Liver | HCC | negative regulation of mitotic cell cycle phase transition | 97/7958 | 179/18723 | 1.03e-03 | 5.91e-03 | 97 |
GO:0007094 | Liver | HCC | mitotic spindle assembly checkpoint | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
GO:0071173 | Liver | HCC | spindle assembly checkpoint | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
GO:0071174 | Liver | HCC | mitotic spindle checkpoint | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
GO:0045841 | Liver | HCC | negative regulation of mitotic metaphase/anaphase transition | 27/7958 | 40/18723 | 1.23e-03 | 6.82e-03 | 27 |
GO:0007088 | Liver | HCC | regulation of mitotic nuclear division | 63/7958 | 110/18723 | 1.24e-03 | 6.85e-03 | 63 |
GO:1901976 | Liver | HCC | regulation of cell cycle checkpoint | 23/7958 | 33/18723 | 1.46e-03 | 7.75e-03 | 23 |
GO:0090231 | Liver | HCC | regulation of spindle checkpoint | 13/7958 | 16/18723 | 1.84e-03 | 9.42e-03 | 13 |
GO:0090266 | Liver | HCC | regulation of mitotic cell cycle spindle assembly checkpoint | 13/7958 | 16/18723 | 1.84e-03 | 9.42e-03 | 13 |
GO:1903504 | Liver | HCC | regulation of mitotic spindle checkpoint | 13/7958 | 16/18723 | 1.84e-03 | 9.42e-03 | 13 |
GO:0031577 | Liver | HCC | spindle checkpoint | 26/7958 | 39/18723 | 1.99e-03 | 1.01e-02 | 26 |
GO:0033046 | Liver | HCC | negative regulation of sister chromatid segregation | 28/7958 | 43/18723 | 2.30e-03 | 1.14e-02 | 28 |
GO:0033048 | Liver | HCC | negative regulation of mitotic sister chromatid segregation | 28/7958 | 43/18723 | 2.30e-03 | 1.14e-02 | 28 |
GO:2000816 | Liver | HCC | negative regulation of mitotic sister chromatid separation | 28/7958 | 43/18723 | 2.30e-03 | 1.14e-02 | 28 |
GO:1902100 | Liver | HCC | negative regulation of metaphase/anaphase transition of cell cycle | 27/7958 | 42/18723 | 3.60e-03 | 1.60e-02 | 27 |
GO:0051784 | Liver | HCC | negative regulation of nuclear division | 34/7958 | 56/18723 | 4.54e-03 | 1.96e-02 | 34 |
GO:1901989 | Liver | HCC | positive regulation of cell cycle phase transition | 63/7958 | 115/18723 | 5.21e-03 | 2.18e-02 | 63 |
GO:0051985 | Liver | HCC | negative regulation of chromosome segregation | 28/7958 | 45/18723 | 5.99e-03 | 2.45e-02 | 28 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC1 | SNV | Missense_Mutation | | c.2765N>T | p.Ser922Phe | p.S922F | Q9H1A4 | protein_coding | tolerated(0.07) | benign(0.347) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ANAPC1 | SNV | Missense_Mutation | | c.1549N>A | p.Pro517Thr | p.P517T | Q9H1A4 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | | c.655N>A | p.Glu219Lys | p.E219K | Q9H1A4 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | | c.415N>C | p.Glu139Gln | p.E139Q | Q9H1A4 | protein_coding | tolerated(0.29) | benign(0.075) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | novel | c.5782N>G | p.Leu1928Val | p.L1928V | Q9H1A4 | protein_coding | tolerated(0.12) | possibly_damaging(0.899) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | | c.5683N>T | p.Pro1895Ser | p.P1895S | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.3620N>A | p.Gly1207Glu | p.G1207E | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
ANAPC1 | SNV | Missense_Mutation | | c.2563N>A | p.Glu855Lys | p.E855K | Q9H1A4 | protein_coding | tolerated(0.76) | benign(0.04) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.4217T>C | p.Leu1406Pro | p.L1406P | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.2050N>C | p.Glu684Gln | p.E684Q | Q9H1A4 | protein_coding | tolerated(0.07) | benign(0.149) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |